Open-label Study of Surufatinib in Japanese Patients
Neuroendocrine Tumors · Non-hematologic Malignancy
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Sep 2024, none posted yet
Counts until it's fixed
Score over time
- Stage
- Phase 1/2
- Patients
- 36 (final count)
- Started
- Sep 2, 2021
- Main results expected
- Sep 6, 2024
- Fully finished
- Jan 17, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Incidence of treatment-emergent adverse events (TEAEs) graded by the Investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0).
Measured over: Up to 2 years
Part 2: Objective response rate. This will be assessed on the proportion of participants with partial response or complete response as determined by the Investigator based on RECIST v1.1
Measured over: Up to 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-09-06, no fading
Raw record changes
- none yet
Trial ID NCT05077384 · record last updated 2025-09-16 · checked 2026-11-09 15:36 UTC